TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03824314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Study: NCT03501459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02863952

Intervention type: OTHER
Group type: OTHER
Intervention: Single photon emission computed tomography myocardial perfusion imaging
Study: NCT01430793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 600,000 Orally
Description: Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 200,000 units IM
Description: Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 200,000 Orally
Description: Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
Study: NCT00026364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT03168594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan cisplatin
Description: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide cisplatin
Description: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
Study: NCT02984618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
Study: NCT02863952

Intervention type: DEVICE
Group type: OTHER
Intervention: novel cadmium-zinc-telluride (CZT) SPECT cameras
Study: NCT03449797

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AVS performed with no intraprocedural rapid cortisol assay
Description: AVS performed plus intraprocedural rapid cortisol assay

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVS performed plus intraprocedural rapid cortisol assay
Description: Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
Study: NCT04355520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
Study: NCT03512574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
Study: NCT01987297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA+Arsenic
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA+Chemo
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.
Study: NCT03512574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and dexmedetomidine
Description: One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
Study: NCT04088799

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00673231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
Study: NCT02984618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural blood patch
Description: Autologous sterile blood (20ml) will be infused in the lombar epidural space.
Study: NCT04752046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary cancer resection
Description: patient with maxillary cancer will resected and reconstructed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary cancer resection
Description: patient with maxillary cancer will resected and reconstructed
Study: NCT02130882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benralizumab
Description: An afucosylated humanized antibody to IL-5 receptor alpha
Study: NCT00673231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
Study: NCT02130882

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
Study: NCT00158600

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: alglucosidase alfa
Description: IV infusion of 20mg/kg; qow for 78 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator; qow for 78 weeks.
Study: NCT00673231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
Study: NCT02868918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biodentine
Description: tricalcium silicate cement used to replace the carious dentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer cement
Description: high viscosity glass ionomer used as a base material
Study: NCT03573388

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Lesion OCT assessment
Study: NCT03721744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB201
Description: GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
Study: NCT02868918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DigoraH optium
Description: digital Xray for follow up
Study: NCT03721744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment options
Description: Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
Study: NCT02213367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 20mg (8 weeks)
Study: NCT01969981

Intervention type: PROCEDURE
Intervention: PICC placement with Sherlock 3CG
Study: NCT01668940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lillipops Iced Soothies (4 flavours)
Description: Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mr. Freeze Freezies
Description: There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
Study: NCT02213367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 20mg (8 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 20mg (8 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 40mg
Study: NCT00120627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program (MRP) plus Usual Care
Description: The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care consisting of medication and case management
Description: Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care consisting of medication and case management
Description: Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
Study: NCT02868918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DigoraH optium
Description: digital Xray for follow up
Study: NCT02574039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat bran
Description: 66g oat bran made up in 350ml skimmed milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: refined grain
Description: refined grain product and 350ml skimmed milk
Study: NCT01857141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)
Description: Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: patients in the control groups received the equivalent volume of normal saline.
Study: NCT03386435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
Study: NCT00442923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coreg
Study: NCT05142449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxilan
Description: Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
Study: NCT00856830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Drug Combination
Description: This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
Study: NCT01031953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Description: Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
Study: NCT00442923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coreg
Study: NCT02213367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastin
Description: 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastin
Description: 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastin
Description: 80mg
Study: NCT01483053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agomelatine
Description: Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
Study: NCT03961048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally
Description: Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally
Description: Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
Study: NCT04047524

Intervention type: OTHER
Group type: OTHER
Intervention: Monitoring using a FitBit
Description: Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.

Intervention type: OTHER
Group type: OTHER
Intervention: Monitoring using a FitBit
Description: Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
Study: NCT04769687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic Vivomixx®
Description: Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
Study: NCT04522050

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine combined with cisplatin induction chemotherapy
Description: Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.

Intervention type: DRUG
Group type: OTHER
Intervention: concurrent chemoradiotherapy with gemcitabine
Description: followed by concurrent gemcitabine chemoradiotherapy
Study: NCT00826943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Cetirizine 10 mg tab daily x 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 5 mg tab daily x 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily x 7 days
Study: NCT04191031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ioveraº
Description: Cryoneurolysis

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ioveraº sham
Description: ioveraº sham
Study: NCT00260481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometa
Description: Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.